Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· National Cancer Institute (NCI)· Source
Contact: Bogna Brzezinska (principal investigator)
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· Phase 3· NRG Oncology· Source
Contact: Bogna Brzezinska (principal investigator)
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Melanie Clark (principal investigator)
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Melanie Clark (principal investigator)
Active, not recruiting
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT05538897· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Recruiting
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· Phase 2/3· NRG Oncology· Source
Contact: Brian E. Johnson (principal investigator)
Active, not recruiting
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT05053152· Phase 2· NRG Oncology· Source
Active, not recruiting
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647· Phase 2· SWOG Cancer Research Network· Source
Active, not recruiting
Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
NCT04339738· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848· Phase 3· National Cancer Institute (NCI)· Source
Contact: Patricia L. Rich (principal investigator)
Active, not recruiting
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
NCT04268550· Phase 2· SWOG Cancer Research Network· Source
Active, not recruiting
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364· Phase 3· NRG Oncology· Source
Active, not recruiting
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
NCT03811015· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
NCT03348631· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
NCT03701282· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445· Phase 2/3· SWOG Cancer Research Network· Source
Contact: Patricia L. Rich (principal investigator)
Active, not recruiting
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
NCT03654768· Phase 2· SWOG Cancer Research Network· Source
Active, not recruiting
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
NCT03371719· Phase 2· NRG Oncology· Source
Active, not recruiting
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
NCT03419234· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT03367702· Phase 3· NRG Oncology· Source
Active, not recruiting
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03244384· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771· Phase 2· NRG Oncology· Source
Active, not recruiting
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03070886· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
NCT02466971· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179086· Phase 2· NRG Oncology· Source
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Source
Active, not recruiting
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT02003222· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT01368588· Phase 3· Radiation Therapy Oncology Group· Source